What Methanobrevibacter smithii is and why reports mention it

Methanobrevibacter smithii is a methanogenic archaeon, not a bacterium, that consumes hydrogen produced by bacterial fermentation and releases methane (CH₄). It is among the most abundant single microbes in many healthy colons and appears on some consumer panels under “methanogens,” “archaea,” or species-level bins.

Reports care about it because colonic methane production correlates with slow transit and constipation in human studies, and because methane on breath testing is used in small-intestinal and colonic gas workups. A stool abundance line, however, measures who was present in that sample, not how much methane you produced that day or whether breath criteria for intestinal methanogen overgrowth (IMO) are met.

What reports actually resolve

What a stool panel can suggest	What it cannot establish
Relative abundance of M. smithii or methanogen reads in the submitted sample	Positive or negative methane breath test (ppm threshold, fasting protocol)
Presence of methanogen DNA alongside bacterial taxa	SIBO vs IMO distinction (geography of overgrowth)
Shifts between two tests if method and handling are consistent	That methane explains bloating alone without motility and diet context

Assay type matters. 16S panels often miss or under-resolve archaea; shotgun metagenomics and dedicated qPCR for methanogens are more reliable when vendors include them. Reference cohorts vary: low methanogen reads on one platform are not automatically “abnormal” on another.

Methane, motility, and constipation

In cohort and mechanistic work, methane production associates with longer colonic transit and constipation-predominant bowel patterns. M. smithii acts as a hydrogen sink: by removing hydrogen, it can alter the fermentation balance among hydrogen-producing and hydrogen-consuming taxa.

That biology does not translate into a simple report rule. Some constipated patients have high breath methane with documented methanogen activity; others have slow transit without elevated methane. Symptom pattern, medication use, and gut motility assessment usually outweigh a single taxon percentage.

Stool abundance vs breath IMO

Intestinal methanogen overgrowth (IMO) is defined on breath tests (elevated fasting methane, typically ≥10 ppm in commonly cited protocols), not on stool sequencing. Stool can show M. smithii when breath methane is normal, and breath methane can be elevated when stool methanogen reads look unremarkable, timing, segment of gut sampled, and detection method all contribute.

If a report flags “high methanogens” but symptoms fit constipation, the more direct lines of inquiry are bowel habit history, constipation symptom routing, and whether methane breath testing or SIBO breath testing is clinically indicated, not automatic treatment based on archaea abundance alone.

What not to conclude

That high M. smithii on a stool report diagnoses IMO or requires antimethanogenic therapy without breath and clinical context.
That low or undetected methanogens mean methane cannot contribute to your symptoms (breath may still be positive; assay may have missed archaea).
That reducing M. smithii will fix bloating if the mechanism is FODMAP fermentation, visceral hypersensitivity, or pelvic floor dyssynergia, see chronic bloating and FODMAP load.
That archaea are “bad bacteria” to eradicate; they are normal commensals in many people.